CTOs on the Move

Attenua

www.attenua.com

 
Attenua, Inc. is a pharmaceutical company developing antitussive medications.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Attenua raised $35M on 05/01/2018

Similar Companies

Neauvia North America

Our Focus Neauvia North America was established in 2012 and is headquartered in Raleigh, North Carolina. It is the U.S. subsidiary of Neauvia, a global aesthetics brand present in more than 50 countries. Neauvia’s global headquarters is located in Luga...

Amring Pharmaceuticals

Amring promotes health across communities by providing reliable, safe, and affordable medications bringing value to patients and improving quality of life.

Taaneh

Taaneh is engaged in commercializing the use of diamond particles, an inert material, for the authentication, identification and construction of anti-counterfeiting systems. The technology has applications in diverse sectors including the pharmaceutical industry, cosmetics and fragrances, foods, textiles, paint, ink, currency, mechanical components, electronics, and packaging. Taaneh`s IP and patent positions are designed to protect the technology that is the basis for the company`s business plan.

Jaguar Animal Health

Jaguar Animal Health is a company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals. Our products are designed with a thorough understanding of not only species-specific health issues, but also market practices, the economics of current treatment strategies, competitive dynamics, government initiatives, such as concern for extensive antibiotic usage, and effective channels for new product introductions. In addition to Canalevia™ for dogs and Neonorm™ for preweaned dairy calves, we are developing formulations of these products across multiple animal species and market channels. Our management team has significant experience in gastrointestinal and animal health product development. This experience includes the development of crofelemer for human use, from discovery and preclinical and clinical toxicity studies, including the existing animal studies to be used for Canalevia™ regulatory approvals, through human clinical development. Our team also includes individuals who have prior animal health experience at major pharmaceutical companies, including Ciba-Geigy Corp., now Novartis International AG, SmithKline Beecham Corporation, now GlaxoSmithKline LLC, and the animal health group of Pfizer Inc., now Zoetis Inc.

Circle Pharma

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015.